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Abstract
Background: Reduced saturated fat (SFA) consumption is recommended to reduce coronary heart disease (CHD), but there
is an absence of strong supporting evidence from randomized controlled trials (RCTs) of clinical CHD events and few
guidelines focus on any specific replacement nutrient. Additionally, some public health groups recommend lowering or
limiting polyunsaturated fat (PUFA) consumption, a major potential replacement for SFA.
Methods and Findings: We systematically investigated and quantified the effects of increased PUFA consumption, as a
replacement for SFA, on CHD endpoints in RCTs. RCTs were identified by systematic searches of multiple online databases
through June 2009, grey literature sources, hand-searching related articles and citations, and direct contacts with experts to
identify potentially unpublished trials. Studies were included if they randomized participants to increased PUFA for at least 1
year without major concomitant interventions, had an appropriate control group, and reported incidence of CHD
(myocardial infarction and/or cardiac death). Inclusions/exclusions were adjudicated and data were extracted independently
and in duplicate by two investigators and included population characteristics, control and intervention diets, follow-up
duration, types of events, risk ratios, and SEs. Pooled effects were calculated using inverse-variance-weighted random
effects meta-analysis. From 346 identified abstracts, eight trials met inclusion criteria, totaling 13,614 participants with 1,042
CHD events. Average weighted PUFA consumption was 14.9% energy (range 8.0%–20.7%) in intervention groups versus
5.0% energy (range 4.0%–6.4%) in controls. The overall pooled risk reduction was 19% (RR=0.81, 95% confidence interval
[CI] 0.70–0.95, p=0.008), corresponding to 10% reduced CHD risk (RR=0.90, 95% CI=0.83–0.97) for each 5% energy of
increased PUFA, without evidence for statistical heterogeneity (Q-statistic p=0.13; I
2=37%). Meta-regression identified
study duration as an independent determinant of risk reduction (p=0.017), with studies of longer duration showing greater
benefits.
Conclusions: These findings provide evidence that consuming PUFA in place of SFA reduces CHD events in RCTs. This
suggests that rather than trying to lower PUFA consumption, a shift toward greater population PUFA consumption in place
of SFA would significantly reduce rates of CHD.
Please see later in the article for the Editors’ Summary.
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Reduction in saturated fatty acid (SFA) consumption is
traditionally a major focus of dietary recommendations to reduce
coronary heart disease (CHD) risk. However, effects of such a
strategy on clinical CHD events are surprisingly poorly established
in both randomized controlled trials (RCTs) [1–8] and prospective
cohort studies [9]. Prior meta-analyses of RCTs have either
studied the effects of very heterogeneous dietary fat interventions
on very heterogeneous combinations of cardiovascular outcomes
[10], or studied effects of dietary fat interventions on intermediate
risk markers, such as blood lipids [11]. Furthermore, although
dietary guidelines often recommend reduction in SFA consump-
tion, such guidelines often do not highlight any specific nutrient as
preferable for replacing SFA in the diet [12–14], implying that any
macronutrient replacement (unsaturated fats, carbohydrate, or
protein) will produce similar effects.
Consumption of polyunsaturated fatty acids (PUFA) lowers the
total:high-density lipoprotein cholesterol (TC:HDL-C) ratio,
perhaps the best single lipid predictor of CHD risk [15], to a
greater extent than carbohydrate or any other major class of fatty
acids [11]. PUFA consumption may also improve insulin
resistance [16,17] and reduce systemic inflammation [18–20].
These effects on risk factors suggest that PUFA may be an ideal
replacement for SFA in the population. However, surprisingly,
some scientists and organizations argue that consumption of n-6
PUFA, by far the predominant dietary PUFA, will actually
increase CHD risk and have recommended reduced consumption
[21–23], and the Institute of Medicine recommends only a
relatively modest range of 5%–10% energy (%E) consumption
from PUFA [24], limiting its plausibility as a meaningful
replacement for SFA. Several controlled intervention trials have
evaluated whether increasing PUFA consumption, as replacement
for SFA, impacts risk of CHD events but results of these trials have
been inconsistent, with the majority of studies demonstrating no
significant benefits [1–8]. Thus, the demonstration of whether
replacing SFA with PUFA affects CHD outcomes and, if so, the
direction and magnitude of this effect are surprisingly understud-
ied matters of scientific and public health importance. To
investigate and quantify this effect, we performed a systematic
review and meta-analysis of randomized controlled clinical trials
that assessed the impact of increased PUFA consumption, as
replacement for SFA, on CHD endpoints.
Methods
We followed the Quality of Reporting of Meta-analyses
(QUOROM – now PRISMA (http://www.prisma-statement.
org/)) [25] guidelines throughout the design, implementation,
analysis, and reporting of this meta-analysis (see Text S1 for
PRISMA Statement).
Search Strategy
We searched for all RCTs that randomized adults to increased
total or n-6 PUFA consumption for at least 1 year without other
major concomitant interventions (e.g., blood pressure or smoking
control, other multiple dietary interventions, etc.), had an
appropriate control group without this dietary intervention, and
reported (or had obtainable from the authors) sufficient data to
calculate risk estimates with standard errors for effects on
occurrence of ‘‘hard’’ CHD events (myocardial infarction, CHD
death, and/or sudden death). Studies were excluded if they were
observational or otherwise nonrandomized; tested mainly n-3
(rather than total or n-6) PUFA interventions or evaluated only
intermediate (e.g., lipid levels) or ‘‘soft’’ (e.g., angina) CHD
endpoints; or were commentaries, reviews, or duplicate publica-
tions from the same study. We did not restrict to primary or
secondary prevention trials, but included this as a prespecified
factor for assessment of heterogeneity. We included both feeding
trials and trials that utilized dietary advice; for both designs, the
average change in PUFA consumption was assessed. Searches
were performed of literature published through June 2009 using
MEDLINE, Embase, AGRIS, AMED, HMIC, PsycINFO,
Cochrane library, Web of Knowledge, CABI, CINAHL, confer-
ence abstracts (Zetoc), Faculty of 1,000, grey literature sources
(SIGLE), related articles, and hand-searching of reference lists.
Authors and experts were also directly contacted to identify
potentially unpublished trials and, when necessary, request missing
data or clarify methods or results.
A full list of search terms for all databases is available (see Text
S2 for Protocol). For example, for MEDLINE, search terms were
(‘‘Fatty Acids, Omega-6’’[Mesh] OR ‘‘unsaturated fatty acid’’
[tiab] OR ‘‘unsaturated fatty acids’’[tiab] OR ‘‘unsaturated
fat’’[tiab] OR ‘‘unsaturated fats’’[tiab] OR ‘‘polyunsaturated fatty
acid’’[tiab] OR ‘‘polyunsaturated fatty acids’’[tiab] OR ‘‘polyun-
saturated fat’’[tiab] OR ‘‘polyunsaturated fats’’[tiab] OR ‘‘omega-
6’’[tiab] OR ‘‘linoleic’’[tiab] OR ‘‘octadecadienoic acid’’[tiab]
OR ‘‘safflower oil’’[tiab] OR ‘‘sesame oil’’[tiab] OR ‘‘soybean
oil’’[tiab] OR ‘‘soyabean oil’’[tiab] OR ‘‘corn oil’’[tiab]) AND
(‘‘cardiovascular diseases’’[Mesh] OR ‘‘cardiovascular disease’’
[tiab] OR ‘‘cardiovascular diseases’’[tiab] OR ‘‘heart disease’’
[tiab] OR ‘‘heart diseases’’[tiab] OR ‘‘myocardial infarction’’
[tiab] OR ‘‘myocardial infarctions’’[tiab] OR ‘‘heart attack’’[tiab]
OR ‘‘heart attacks’’[tiab] OR ‘‘sudden death’’[tiab] OR ‘‘sudden
deaths’’[tiab] OR ‘‘coronary syndrome’’[tiab]) and NOT (‘‘Fatty
Acids, Omega-3’’[Mesh] OR ‘‘omega-3’’[tw] OR ‘‘n-3’’[tw] OR
‘‘stroke’’[tiab] OR ‘‘strokes’’[tiab] OR ‘‘cerebrovascular acci-
dent’’[tiab] OR ‘‘cerebrovascular accidents’’[tiab] OR ‘‘Case
Reports’’[Publication Type]); limited to humans, adults, and
clinical trials or RCTs; through June 2009 without other date or
language limitations. For other databases, search terms followed
similar concepts with variations based on the database structure.
Selection of Articles
Of 346 identified articles, 290 were excluded based upon review
of the title and abstract (Figure 1). Full texts of the remaining 54
manuscripts were independently assessed in duplicate by two
investigators to determine inclusion/exclusion. Forty-six studies
were excluded because they did not meet inclusion and exclusion
criteria (Table S1). The independent duplicate inclusion/exclusion
adjudications were 96% concordant on initial comparison. The
rare differences were resolved by group consultation among all
investigators, with unanimous consensus.
Data Extraction
For each of the final identified trials, data were extracted
independently and in duplicate by two investigators, including
years the study was performed and reported, population
characteristics, control and intervention diets, duration of follow-
up, numbers and types of first CHD events during follow-up, risk
ratios (RRs), and standard errors (SEs) of these estimates. When
the latter were not available, they were directly calculated using
binomial tests of proportions, given that most studies reported RRs
rather than incidence rates; stronger findings were seen if SEs were
directly calculated using person-time at risk for two reports using
incidence rates (unpublished data). Differences in data extracted or
quality assessment scores between investigators were very unusual
and were resolved by consensus. Several different criteria have
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analyses, although the validity and utility of different quality scores
has been debated [26]. We assessed study quality using the
validated Jadad scale [27], which includes criteria relating to
randomization, blinding, and withdrawals and dropouts that are
together summed to generate an overall quality score between 0
and 5. Following prior precedent [27], quality scores of 0–2
indicated lower-quality trials, and quality scores of 3–5 indicated
higher-quality trials.
Statistical Analysis
The overall pooled effect was calculated using random effects
meta-analysis, which accounts for heterogeneity in treatment
effects among studies, using the methods of Dersimonian and
Laird [28] with inverse-variance (SE) weighting. Heterogeneity
between studies was evaluated using the Dersimonian and Laird
Q-statistic, the I
2 statistic, and meta-regression [28,29]. Potential
for publication bias was assessed by visually inspecting a funnel
plot of the treatment effect versus SE [30] and statistically using
the Begg adjusted-rank correlation test [31]. Prespecified potential
sources of heterogeneity were explored using stratified inverse-
variance weighted random effects meta-analysis and inverse-
variance weighted metaregression, including trial duration (, or
$ median for all trials), study population (primary versus
secondary prevention), and overall quality score (0–2 versus
3–5). We also performed post-hoc secondary analyses for CHD
mortality alone and total mortality, as well as based on selected
study characteristics, such as enrollment design (excluding trials
with open enrollment), extent of blinding, and type of dietary
intervention (provision of meals versus dietary advice). Analyses
were performed using STATA 10.1 (College Station, TX), with
two-tailed alpha ,0.05.
Results
The identified RCTs included a total of 1,042 CHD events
among 13,614 participants (Table 1) [1–8,32–34]. Average PUFA
consumptionrangedfrom4.0%Eto6.4%E(weightedmean5.0%E)
in the control groups and from 8.0%E to 20.7%E (weighted mean
14.9%E) in the intervention groups. Diet was assessed in the
majority of trials by either direct analysis of provided foods or by
multiple-day weighed diet records. Four trials evaluated secondary
prevention populations, three trials evaluated primary prevention
populations, and one trial evaluated a mixed population of
individuals with and without established CHD. Many of the trials
had design limitations, such as single-blinding, inclusion of
electrocardiographically defined clinical endpoints, or open enroll-
ment. All trials utilized blinded endpoint assessment. Quality scores
were in the modest range and relatively homogeneous: all trials had
quality scores of either 2 or 3. Combining all trials, the pooled risk
Figure 1. Results of the systematic search strategy and study selection process.
doi:10.1371/journal.pmed.1000252.g001
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p=0.008) (Figure 2). Statistical evidence for substantial between-
study heterogeneity was not present (Q-statistic p=0.13; I
2=37%).
In evaluating potential for publication bias, the trial by Watts et al.
[8] was clearly a potential outlier both in terms of sample size and
risk reduction. Excluding this trial, there was little change in the
overall pooled result: RR=0.82, 95% CI 0.70–0.95; p heterogene-
ity=0.11, I
2=42%. Visual inspection of the resulting funnel plot
indicated some potential for publication bias (Figure S1), with a
borderline Begg’s test (continuity corrected p=0.07), although such
determinations are limited when the number of studies is relatively
small.
Weighted by the inverse-variance of each trial, the mean
increase in PUFA consumption in the intervention group,
compared to the control group, was 9.9%E, corresponding to a
risk reduction for each 5%E greater PUFA consumption of 10%
(RR=0.90, 95% CI 0.83–0.97). Weighted by the inverse-variance
of each trial, the mean decrease in blood total cholesterol (TC)
levels in the intervention group, compared to the control group,
was 0.76 mmol/l (29 mg/dl), corresponding to an observed risk
reduction of 24% for each 1 mmol/l reduction in TC (RR=0.76,
95% CI=0.62–0.93).
The median duration of all trials was 4.25 years. Among the
four trials with duration ,4.25 years, the pooled RR was 0.91
(95% CI 0.76–1.10). Among the four trials with duration $4.25
years, the pooled RR was 0.73 (95% CI 0.61–0.87). In the four
trials that evaluated exclusively or predominantly primary
prevention populations, the pooled RR was 0.76 (95% CI 0.55–
1.04). In the four trials that evaluated secondary prevention
populations, the pooled RR was 0.84 (95% CI 0.72–0.98). For the
six trials with a quality score of 2, the pooled RR was 0.78 (95%
CI 0.66–0.91); for the two trials with a quality score of 3, the
pooled RR was 0.91 (95% CI 0.63–1.31). Evaluating each of these
potential sources of variation together in a metaregression model,
study duration (p=0.016), but not primary versus secondary
prevention (p=0.71) nor quality score (p=0.78), was identified as
a significant independent determinant of the extent of risk
reduction. For each additional year of study duration, PUFA
consumption lowered the relative risk of CHD events by an
additional 9.2% in the intervention group (95% CI 1.7%–16.8%),
compared with the control group. In secondary analyses restricted
to CHD mortality alone (855 events, including 312 events from the
full mortality report of one trial [34]), the pooled RR was 0.80
(95% CI 0.65–0.98). Evaluating total mortality due to all causes
(2,472 events), the pooled RR was 0.98 (95% CI 0.89–1.08).
The overall pooled result for CHD events was not substantially
altered in post-hoc secondary analyses based on specific study
design characteristics. For example, excluding the three reports
(two trials) with open enrollment, the overall pooled RR was 0.83
(95% CI 0.72–0.95, p=0.006). Excluding the Finnish mental
hospital trial (two reports) that used a cluster-randomization
design, the overall pooled RR was 0.87 (95% CI 0.76–1.00,
p=0.05). Only two trials were double-blind; restricting to these
two studies, the pooled RR was 0.91 (95% CI 0.63–1.31), with
Figure 2. Meta-analysis of RCTs evaluating effects of increasing PUFA consumption in place of SFA and occurrence of CHD events.
doi:10.1371/journal.pmed.1000252.g002
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Restricting to the four reports that provided meals (i.e., that were
feeding trials), the pooled RR was 0.76 (95% CI 0.55–1.04,
p=0.08). Restricting to the four trials that provided mainly dietary
advice, the pooled RR was 0.84 (95% CI 0.72–0.98, p=0.03).
None of these subgroup analyses were significantly different from
the main pooled result, as demonstrated by the 95% CIs in each
subgroup analysis including the value of the main pooled RR
estimate of 0.81.
Discussion
In this meta-analysis of RCTs, increasing PUFA consumption
as a replacement for SFA reduced the occurrence of CHD events
by 19%; each 5%E greater PUFA consumption reduced CHD risk
by 10%. Whereas nearly all these trials were insufficiently powered
to detect a significant effect individually, the pooled results
demonstrate a significant benefit of replacing PUFA for SFA on
clinical CHD events. Thus, this is only the second dietary
intervention, together with consumption of long-chain omega-3
fatty acids (fish oil) [7,35–37], that has now been clearly
demonstrated to reduce cardiovascular events in RCTs.
In short-term feeding trials, each 5%E of PUFA replacing SFA
lowers low-density lipoprotein cholesterol (LDL-C) by 10 mg/dl,
without an appreciable reduction in HDL-C, producing a
lowering of the TC:HDL-C ratio by 0.16; this can be compared
to no significant change in the TC:HDL-C ratio when SFA is
replaced by carbohydrate [11]. In observational studies of adults
aged 40–59 y, each 1 unit lower TC:HDL-C is associated with
44% lower risk of CHD [15]. Based on these two sets of data, a
5%E increase in PUFA replacing SFA would be predicted, based
on TC:HDL-C effects alone, to reduce occurrence of CHD by 9%
(Figure 3). Thus, the 10% risk reduction for a 5%E increase in
PUFA replacing SFA demonstrated in the present meta-analysis of
RCTs of clinical CHD outcomes is remarkably consistent with
effects that would be predicted based on extension of the
demonstrated lipid changes in short-term intervention trials to
epidemiologic associations between TC:HDL-C and CHD risk. A
slightly greater risk reduction in studies of CHD events, compared
with predicted effects based on lipid changes alone (Figure 3), is
consistent with potential additional benefits of PUFA on other
nonlipid pathways of risk such as insulin resistance [16,17] and
systemic inflammation [18–20]. Indeed, the impact of these
additional benefits may be underestimated—the inevitable non-
compliance in long-term dietary trials would attenuate true
benefits, suggesting that the 10% risk reduction for a 5%E
increase in PUFA in the present analysis may underestimate the
full effects. Additionally, our analysis of heterogeneity indicates
Figure 3. Effects on CHD risk of consuming PUFA, carbohydrate, or MUFA in place of SFA. Predicted effects are based on changes in the
TC:HDL-C ratio in short-term trials (e.g., each 5%E of PUFA replacing SFA lowers TC:HDL-C ratio by 0.16) [11] coupled with observed associations
between the TC:HDL-C ratio and CHD outcomes in middle-aged adults (each 1 unit lower TC:HDL-C is associated with 44% lower risk of CHD) [15].
Evidence for effects of dietary changes on actual CHD events comes from the present meta-analysis of eight RCTs for PUFA replacing SFA and from
the Women’s Health Initiative RCT for carbohydrate replacing SFA (n=48,835, ,3%E reduction in SFA over 8 years) [39]. Evidence for observed
relationships of usual dietary habits with CHD events comes from a pooled analysis of 11 prospective cohort studies [38].
doi:10.1371/journal.pmed.1000252.g003
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benefits of increasing PUFA consumption accrue over time.
When all trials were pooled, CHD risk was reduced by 24% for
each 1 mmol/l reduction in TC (95% CI 7%–38%). This finding
is consistent with results of observational studies of usual TC levels
and CHD risk. In a pooled analysis from 61 prospective cohort
studies including nearly 900,000 adults, each 1 mmol/l lower TC
was associated with 28% lower risk of CHD death in adults aged
60–69 (RR=0.72, 95% CI 0.69–0.74) and 42% lower risk of
CHD death in adults aged 50–59 (RR=0.58, 95% CI 0.56–0.61)
[15], the ranges of ages included in the present trials. A
comparison of our findings to those of long-term prospective
observational studies of PUFA consumption is also informative.
The most robust evidence to date comes from a recent report of
pooled individual-level data from 11 cohort studies in America,
Europe, and Israel, including 344,696 adults and 5,249 CHD
events [38]. Each 5%E of greater PUFA consumption, as a
replacement for SFA, was associated with 13% lower risk of CHD
(RR=0.87, 95% CI 0.77–0.97) (Figure 3). Our finding in RCTs of
10% lower risk of CHD for each 5%E of greater PUFA
consumption, as a replacement for SFA, strongly supports both
the causality and magnitude of these observational findings.
Because each of the RCTs in this meta-analysis tested the effects
of consuming PUFA in place of SFA, the present findings cannot
distinguish between potentially distinct benefits of increasing
PUFA versus decreasing SFA. Thus, the present evidence alone
is insufficient to conclude that increasing PUFA in place of any
other nutrient will reduce CHD events. Notably, this evidence is
similarly insufficient to conclude that decreasing SFA in place of
any other nutrient will reduce CHD events. However, our findings
indicate that a strategy of replacing SFA with PUFA is likely to
reduce the occurrence of CHD.
Other lines of evidence—in particular, findings from RCTs of
lipid risk factors and prospective cohort studies of CHD events—
can provide insights into whether benefits may be more strongly
related to reduced SFA, increased PUFA, or both. Based on either
the predicted effects on TC:HDL-C, the results of a large RCT
[39], or a pooled analysis of 11 prospective cohort studies [38],
replacement of SFA with carbohydrate does not lower CHD risk
(Figure 3). Evidence for CHD effects of replacing SFA with
monounsaturated fatty acids (MUFA) is mixed (Figure 3);
randomized trials have not tested the effects of replacing SFA
with MUFA. Thus, the evidence is most consistent and robust for
CHD benefits when SFA is replaced with PUFA, rather than with
MUFA or carbohydrate, suggesting that lower risk may be more
strongly related to increased PUFA rather than decreased SFA
consumption. Recent ecological studies across nations over time
also support this contention, with changes in population CHD
mortality being most strongly related to increased consumption of
vegetable oils that contained PUFA, particularly the n-3 PUFA
alpha-linolenic acid, rather than decreases in animal fats or
increases in overall vegetable consumption [40]. Further studies
are needed to evaluate the role of MUFA or protein as a
replacement for other macronutrients on risk of CHD.
The eight trials in this meta-analysis were performed and reported
with a relatively regular distribution over nearly three decades
between 1968 and 1992. This broad time span could increase
generalizability, and there is likely little reason to believe that the
biologic effects of PUFA have changed in recent years. The use of
random-effects meta-analysis allowed the pooling and estimation of
overall variance of different trials that may also each be estimating a
different ‘‘true’’ effect. All of these RCTs had blinded endpoint
ascertainment that would limit the magnitude of potential differential
(biased) assignment of types of events or causes of death.
Manyof the identifiedrandomized trialsin ourmeta-analysis had
important design limitations (Table 1). For example, some trials
provided all or most meals, increasing compliance but perhaps
limiting generalizability to effects of dietary recommendations
alone; whereas other trials relied only on dietary advice, increasing
generalizability to dietary recommendations but likely underesti-
mating efficacy due to noncompliance. Several of these trials were
not double-blind, raising the possibility of differential classification
of endpoints by the investigators that could overestimate benefits of
the intervention. One trial used a cluster-randomization cross-over
designthat intervened onsites ratherthan individuals;and two trials
used open enrollment that allowed participants to both drop-in and
drop-out during the trial. The methods for estimating and reporting
PUFA and SFAconsumptionineach trialvaried, whichcould cause
errors in our estimation of the quantitative benefit per %E
replacement. One of the trials also provided, in addition to the
main advice to consume soybean oil, sardines to the intervention
group [3], so that observed benefits may be at least partly related to
marine omega-3 PUFA rather than total PUFA consumption.
Several of the trials specified use of vegetable oils containing, in
addition to omega-6 PUFA, small amounts of the omega-3 PUFA
alpha-linolenic acid [2–5,8], although additional benefits of this
plant-derived omega-3, compared with seafood-derived omega-3,
are not yet clearly established [41].
Given these limitations of each individual trial, the quantitative
pooled risk estimate should be interpreted with some caution.
Nevertheless, this is the best current worldwide evidence from
RCTs for effects on CHD events of replacing SFA with PUFA,
and, as discussed above, the pooled risk estimate from this meta-
analysis (10% lower risk per 5%E greater PUFA) is well within the
range of estimated benefits from randomized controlled feeding
trials of changes in lipid levels (9% lower risk per 5%E greater
PUFA) and prospective observational studies of clinical CHD
events (13% lower risk per 5%E greater PUFA). The consistency
of the findings across these different lines of evidence provides
substantial confidence in both the qualitative benefits and also a
fairly narrow range of quantitative uncertainty.
As in any meta-analysis, publication bias is a potential
limitation. It seems unlikely that large dietary clinical trials would
have been performed and not reported without any knowledge of
the community of experts, and if smaller trials were performed and
unpublished, their addition would be unlikely to substantially alter
the pooled risk estimate given the numbers of subjects and events
currently included. Additionally, our direct contact with experts
minimized the possibility of missing unpublished studies. The
findings of this meta-analysis cannot be extrapolated to effects of
replacing SFA with carbohydrate or MUFA (Figure 3), which were
not evaluated in the present trials. Results should also not be
extrapolated to effects of increasing PUFA as replacement for
carbohydrate, although based on changes in TC:HDL-C in
feeding studies [11], and observed relationships with clinical events
in cohort studies [38,42], one would predict CHD benefit from
such replacement. Future trials should investigate these other
dietary interventions, in particular increasing PUFA consumption
as a replacement for carbohydrate and also MUFA.
This current meta-analysis of RCTs of clinical CHD events,
together with consistent findings from both prospective cohort
studies of clinical CHD events and RCTs of intermediate risk
factors, provides strong concordant evidence that consumption of
PUFA, in place of SFA, lowers CHD risk. Our findings have
several immediate implications. First, our results, together with
data from other research paradigms discussed above, indicate that
evidence-based population- and individual-level recommendations
to reduce SFA consumption should specify the importance of
Meta-analysis: PUFA Intake and CHD
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used vegetable oils containing small amounts of plant-derived n-3
PUFA in addition to omega-6 PUFA, our findings as well as those
of ecologic studies [40] would support focus on n-3 PUFA-
containing vegetable oils, such as soybean or canola, to increase
population PUFA intake. For example, daily consumption of 20 g
soybean oil or 30 g canola oil, as an isocaloric replacement for
other macronutrients, would increase PUFA consumption by
,5%E on a 2000 kcal/d diet [43]. Third, our findings
demonstrate reductions in CHD events, and no evidence for
increased risk, in long-term trials utilizing PUFA consumption at
very high levels (mean=14.9%E, range 8.0%E –20.7%E). This
suggests that current recommendations for an upper limit of
PUFA consumption at 10%E [12–14] need to be revisited,
particularly as PUFA appears to be the primary evidence-based
replacement for SFA. Finally, whereas on a population-level even
a small shift from SFA to PUFA consumption would produce
meaningful reductions in CHD risk, the relatively modest
magnitude of plausible benefit (,10% lower risk for 5%E
replacement) indicates a need for substantial policy focus on other
dietary risk factors for CHD [44], in particular high consumption
of salt and low consumption of seafood, whole grains, fruits, and
vegetables.
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Background. Coronary heart disease (CHD) is the leading
cause of death among adults in developed countries. It is
caused by disease of the coronary arteries, the blood vessels
that supply the heart with oxygen and nutrients. With age,
inflammatory deposits (atherosclerotic plaques) coat the
walls of these arteries and restrict the heart’s blood supply,
causing angina (chest pains that are usually relieved by rest),
shortness of breath, and, if these plaques rupture or break,
heart attacks (myocardial infarctions), which can reduce the
heart’s function or even be fatal. The key risk factors for CHD
are smoking, physical inactivity, and poor diet. Blood
cholesterol levels are altered by consuming dietary fats.
There are three main types of dietary fats—‘‘saturated’’ fatty
acids (SFA) and unsaturated fatty acids; the latter can be
‘‘mono’’ unsaturated (MUFA) or ‘‘poly’’ unsaturated (PUFA).
Eating SFA-rich foods (for example, meat, butter, and cheese)
increases the amount of LDL-C in the blood but also
increases HDL-C (the ‘‘good’’ cholesterol) and decreases
triglycerides. Eating foods that are rich in unsaturated fatty
acids (for example, vegetable oils and fatty fish) decreases
the amount of LDL-C and triglycerides in the blood and also
raises HDL-C.
Why Was This Study Done? Because of the connection
between eating SFA and high blood LDL-C levels, reduced
SFA consumption is recommended as a way to avoid CHD.
However, the evidence from individual randomized controlled
trials that have studied CHD events (such as heart attacks and
CHD-related deaths) have been mixed and could not support
this recommendation.Furthermore,dietaryrecommendations
to reduce SFA have generally not specified any replacement,
i.e., whether SFA should be replaced with carbohydrate,
protein, or unsaturated fats. Because of their beneficial effects
on blood LDL-C and HDL-C levels, PUFA could be one
important replacement for SFA, but, surprisingly, some
experts argue that eating PUFA could actually increase CHD
risk. Consequently, some guidelines recommend that PUFA
consumption should be limited or even reduced. In this
systematic review (a study that uses predefined criteria to
identify all the research on a specific topic) and meta-analysis
(a statistical method for combining the results of several
studies) of randomized controlled trials, the researchers assess
the impact of increased PUFA consumption as replacement
for SFA on CHD events.
What Did the Researchers Do and Find? The researchers’
search of the published literature, ‘‘grey’’ literature (doctoral
dissertations, technical reports, and other documents not
printed in books and journals), and contacts with relevant
experts identified eight trials in which participants were
randomized to increase their PUFA intake for at least a year
and in which CHD events were reported. 1,042 CHD events
were recorded among the 13,614 participants enrolled in
these trials. In their meta-analysis, the researchers found that
on average the consumption of PUFA accounted for 14.9% of
total energy intake in the intervention groups compared with
only 5% of total energy intake in the control groups.
Participants in the intervention groups had a 19% reduced
risk of CHD events compared to participants in the control
groups. Put another way, each 5% increase in the proportion
of energy obtained from PUFA reduced the risk of CHD events
by 10%. Finally, the researchers found that the benefits
associated with PUFA consumption increased with longer
duration of the trials.
What Do These Findings Mean? These findings suggest
that the replacement of some dietary SFA with PUFA reduces
CHD events. Because the trials included in this study looked
only at replacing SFA with PUFA, it is not possible from this
evidence alone to distinguish between the benefits of
reducing SFA and the benefits of increasing PUFA.
Furthermore, the small number of trials identified in this
study all had design faults, so the risk reductions reported
here may be inaccurate. However, other lines of evidence
(for example, observational studies that have examined
associations between the fat intake of populations and their
risk of CHD) also suggest that consumption of PUFA in place
of SFA reduces CHD risk. Thus, in the light of these findings,
future recommendations to reduce SFA in the diet should
stress the importance of replacing SFA with PUFA rather than
with other forms of energy, and the current advice to limit
PUFA intake should be revised.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000252.
N The American Heart Association provides information
about all aspects of coronary heart disease for patients,
caregivers, and professionals, including advice on dietary
fats (in several languages)
N The UK National Health Service Choices Web site provides
information about coronary heart disease
N Eatwell, a resource provided by the UK Food Standards
Agency, gives advice on all aspects of healthy eating,
including fat consumption
N MedlinePlus provides links to further resources on
coronary heart disease and on cholesterol (in English and
Spanish)
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